653 related articles for article (PubMed ID: 11852811)
1. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
4. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
5. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
6. [Fibrinolytic system in bronchial asthma after prednisone treatment].
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Pol Merkur Lekarski; 2000 Jan; 7(43):9-11. PubMed ID: 10765644
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
10. [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms].
Białkowska A; Kotschy M; Betlejewski S; Burduk D
Otolaryngol Pol; 1995; 49 Suppl 20():84-7. PubMed ID: 9454229
[TBL] [Abstract][Full Text] [Related]
11. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
[TBL] [Abstract][Full Text] [Related]
12. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
13. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
14. [Hemostatic disturbances in chronic myeloid leukemia].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
[TBL] [Abstract][Full Text] [Related]
15. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
16. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease.
Wieczór R; Wieczór AM; Kulwas A; Rość D
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31336615
[No Abstract] [Full Text] [Related]
17. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic response to retinal detachment surgery under general or local anesthesia.
Malukiewicz-Wiśniewska G; Kotschy M
Eur J Ophthalmol; 2001; 11(1):66-72. PubMed ID: 11284489
[TBL] [Abstract][Full Text] [Related]
19. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal fluid and plasma fibrinolytic activity in women with pelvic inflammatory disease.
Dörr PJ; Brommer EJ; Dooijewaard G; Vemer HM
Thromb Haemost; 1992 Aug; 68(2):102-5. PubMed ID: 1412151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
